Terrance P. Coyne, EVP & CFO at Royalty Pharma plc (RPRX), sold 200,000 shares at $45.09 ($9.0M) on 2021-03-03, disclosed to the SEC on 2021-03-05.
Open-market sale of $9.0M RPRX by EVP & CFO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $43.71 | 29,820 | $1.3M | 14.6% |
| 2 | $43.71 | 29,820 | $1.3M | 14.6% |
| 3 | $45.09 | 57,723 | $2.6M | 29.1% |
| 4 | $45.09 | 57,723 | $2.6M | 29.1% |
| 5 | $45.86 | 11,001 | $505K | 5.6% |
| 6 | $45.86 | 11,001 |
| $505K |
| 5.6% |
| 7 | $46.83 | 1,456 | $68K | 0.8% |
| 8 | $46.83 | 1,456 | $68K | 0.8% |
| Total | $44.79 avg | 200,000 | $9.0M | 100% |
| Filing → |
| RPRX | SELL | 2026-04-30 | $1.7M | — | Filing → |
| RPRX | SELL | 2026-04-02 | $1.7M | — | Filing → |
| RPRX | SELL | 2026-03-25 | $3.2M | — | Filing → |